Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)

被引：1
|
作者：
Shitara, K.
Lordick, F.
Bang, Y-J
机构：
来源：
LANCET | 2023年 / 402卷 / 10398期
关键词：
D O I：
10.1016/S0140-6736(23)01481-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：290 / 290
页数：1
相关论文
共 33 条
  • [21] Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
    Boku, Narikazu
    Omori, Takeshi
    Shitara, Kohei
    Sakuramoto, Shinichi
    Yamaguchi, Kensei
    Kato, Ken
    Kadowaki, Shigenori
    Tsuji, Kunihiro
    Ryu, Min-Hee
    Oh, Do-Youn
    Oh, Sang Cheul
    Rha, Sun Young
    Lee, Keun-Wook
    Chung, Ik-Joo
    Sym, Sun Jin
    Chen, Li-Tzong
    Chen, Jen-Shi
    Bai, Li-Yuan
    Nakada, Takashi
    Hagihara, Shunsuke
    Makino, Reina
    Nishiyama, Eiji
    Kang, Yoon-Koo
    GASTRIC CANCER, 2024, 27 (06) : 1287 - 1301
  • [22] Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
    Catenacci, Daniel V. T.
    Tebbutt, Niall C.
    Davidenko, Irina
    Murad, Andre M.
    Al-Batran, Salah-Eddin
    Ilson, David H.
    Tjulandin, Sergei
    Gotovkin, Evengy
    Karaszewska, Boguslawa
    Bondarenko, Igor
    Tejani, Mohamedtaki A.
    Udrea, Anghel A.
    Tehfe, Mustapha
    De Vita, Ferdinando
    Turkington, Cheryl
    Tang, Rui
    Ang, Agnes
    Zhang, Yilong
    Hoang, Tien
    Sidhu, Roger
    Cunningham, David
    LANCET ONCOLOGY, 2017, 18 (11): : 1467 - 1482
  • [23] JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Alsina, Maria
    Weinberg, Zev A.
    Chau, Ian
    Zhu, Jin
    Chan, Wai Y.
    Patel, Premal H.
    Meng, Raymond D.
    Ajanl, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial (vol 376, pg 687, 2010)
    Bang, Y-J
    Van Cutsem, E.
    Feyereislova, A.
    LANCET, 2010, 376 (9749): : 1302 - 1302
  • [25] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 18, pg 904, 2017)
    Baselga, J.
    Im, S-A
    Iwata, H.
    LANCET ONCOLOGY, 2019, 20 (02): : E71 - E72
  • [26] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Kang, Yoon-Koo
    Boku, Narikazu
    Satoh, Taroh
    Ryu, Min-Hee
    Chao, Yee
    Kato, Ken
    Chung, Hyun Cheol
    Chen, Jen-Shi
    Muro, Kei
    Kang, Won Ki
    Yeh, Kun-Huei
    Yoshikawa, Takaki
    Oh, Sang Cheul
    Bai, Li-Yuan
    Tamura, Takao
    Lee, Keun-Wook
    Hamamoto, Yasuo
    Kim, Jong Gwang
    Chin, Keisho
    Oh, Do-Youn
    Minashi, Keiko
    Cho, Jae Yong
    Tsuda, Masahiro
    Chen, Li-Tzong
    LANCET, 2017, 390 (10111): : 2461 - 2471
  • [27] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 431, 2016)
    Cristofanilli, M.
    Turner, N. C.
    Bondarenko, I
    LANCET ONCOLOGY, 2016, 17 (07): : E270 - E270
  • [28] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016)
    Cristofanilli, M.
    Turner, N. C.
    Bondarenko, I
    LANCET ONCOLOGY, 2016, 17 (04): : E136 - E136
  • [29] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Lordick, F.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Van Cutsem, E.
    Plazas, J. Gallego
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Soo, H. H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Cao, Y. J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1321 - S1321
  • [30] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Lordick, F.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    van Cutsem, E.
    Gallego Plazas, J.
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Soo, H. H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Cao, Y. J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1524
1234